store at low temperature
store at -80°C
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 438.00 | |
5 mg | In stock | $ 987.00 | |
10 mg | In stock | $ 1,380.00 | |
25 mg | In stock | $ 1,980.00 | |
50 mg | In stock | $ 2,770.00 | |
100 mg | In stock | $ 3,730.00 |
Description | Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC). |
Molecular Weight | N/A |
CAS No. | 1228763-95-8 |
store at low temperature
store at -80°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Monalizumab 1228763-95-8 Cell Cycle/Checkpoint Immunology/Inflammation IFNAR Chk inhibitor inhibit